APR 24, 2018 7:40 AM PDT

Discovery of a Protein led to a Therapeutic Approach For Asthma

WRITTEN BY: Nouran Amin

Asthma is a chronic respiratory disease . It is common and affects more than 300 million people worldwide and over 40 million people in the United States. Individuals with asthma and other respi ratory il lnesses have recurrent episodes of chest tightness, wheezing, pulmonary obstruction and severe respiratory problems.

Now, a new treatment for asthma and other respiratory disorders was discovered by researchers at Rutgers New Jersey Medical School, findings were published in Science Translational Medicine. The discovery could lead to an increased effectiveness of drug therapy for millions of sufferers.

Lead investigator and immunologist, Luis Ulloa, from Rutgers New Jersey Medical School, and collaborators from Shanghai University in China studied over 6,000 compounds and noted a drug (TSG12) that relaxes the smooth muscles and opens the airways in those with asthma. The drug treatment is not toxic in human cells and works to target pulmonary resistance in egg -and dust mite-induced asthma. "It is not a cure, but I think this treatment will give people a lot of hope," said Ulloa. "There are a growing number of patients with no alternative because the current treatments either have critical side effects or aren't working. We hope this will give patients a better option."

This four-year research study found that the metallothionein-2 (MT-2) protein in the asthmatic lung tissue relaxes smooth muscle cells and opens the airways. This allows individuals suffering from asthma to breathe. The investigators also discovered that MT-2 was signifcantly lower in asthmatic lung tissue. Additionally , mouse models without the MT-2 protein were two-times more prone to asthma and therefore , treating them with MT-2 had a positive effect on breathing issues related to asthma.

Image via SimpleBiology.com

The identification of the MT-2 protein and its relationship to asthmatic lung tissue was discovered after the transfer of short electrical pulses into mouse models through electroacupuncture needles. This allowed researchers to also identify the specific drug (TSG12) that is believed to provide better therapeutic treatment options for asthma and other respiratory disorders.

The discovery of the MT-2 protein developed the TSG12 treatment. The tretament is seen to relax the smooth muscle cells, expand the pulmonary airways, reduce pulmonary resistance, and be of a better efficacy than current FDA-approved treatments, such as bronchodilator inhalers, which is currently in use by most individuals with a sthma .

Even though treating asthma and respiratory conditions like chronic obstructive pulmonary disease (COPD) with a bronchodilator in order to relax and improve the airways in the lungs making breathing easier, the TSG12 drug is a promising therapeutic strategy, however, the mechanism behind how this drug works is still misunderstood .

Luis Ulloa believes the problem with the current approved drugs is that they have critical side effects that decrease the strength of the immune system and increase the risk of secondary infections. Additionally, he believes that these drugs do not provide enough relief to almost one-third of asthmatic individuals and over a period of time patients do not respond to treatment and have persistent uncontrolled symptoms . "We found that the TSG12 used in the study is both non-toxic and more effective in reducing pulmonary resistance and could be a promising therapeutic approach for treating asthma without losing their effectiveness overtime," explains Ulloa.

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 11, 2020
Drug Discovery & Development
APR 11, 2020
Remdesivir Improves COVID-19 Symptoms in 68% of Patients in Early Study
An early analysis of remdesivir, a drug developed by pharmaceutical firm Gilead, has shown that it may have improved sev ...
APR 20, 2020
Cancer
APR 20, 2020
Expanding the Diagnostic Toolkit in Cancer Research with isomiRNAs
Esophageal cancers are one of the more common cancers around the world, with an unfortunately poor prognosis. The five-y ...
MAY 04, 2020
Immunology
MAY 04, 2020
GeoVax and Sino Bio Collaborate on COVID-19 Vaccine Work
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and ...
MAY 02, 2020
Drug Discovery & Development
MAY 02, 2020
Glioblastoma Treatment Using Schizophrenic Drug Plus Radiation
A therapeutic used for the treatment of schizophrenia could be a gateway for targeting glioblastoma, one of the deadlies ...
MAY 12, 2020
Drug Discovery & Development
MAY 12, 2020
Novel Drug Approved for Non-Small Cell Lung Cancer
The US Food and Drug Administration (FDA) recently approved a therapeutic for treating metastatic non-small cell lung ca ...
MAY 26, 2020
Drug Discovery & Development
MAY 26, 2020
Everyone Can Produce Antibodies Against COVID-19
Researchers at Rockefeller University in New York have found that most people exposed to COVID-19, and who experience sy ...
Loading Comments...